PARP Inhibitors in Metastatic Prostate Cancer: Efficacy, Trials, and Combination Therapies

Key Takeaways

• Olaparib significantly improved radiographic progression-free survival and overall survival in metastatic prostate cancer with HRR gene alterations.
• Safety profiles of PARP inhibitors were consistent with known effects, with manageable adverse events observed.
• The PROfound trial underscores the importance of genetic testing to guide personalized treatment decisions in prostate cancer.
• PARP inhibitors offer a promising targeted therapy for patients with HRR gene alterations, enhancing treatment personalization.